# The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

> **NCT02430311** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 36 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Paclitaxel
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02430311
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-10
- **Primary completion:** 2016-07-27
- **Final completion:** 2017-04-28
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430311, "The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02430311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*